These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 28933798

  • 1. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG.
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D, Ellis D, Canafax DM, Combs D, Druzgala P, Milner PG, Midei MG.
    Thromb Haemost; 2017 Apr 03; 117(4):706-717. PubMed ID: 28180234
    [Abstract] [Full Text] [Related]

  • 3. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
    Whitlock RP, Fordyce CB, Midei MG, Ellis D, Garcia D, Weitz JI, Canafax DM, Albrecht D, Milner PG.
    Thromb Haemost; 2016 Aug 01; 116(2):241-50. PubMed ID: 27173100
    [Abstract] [Full Text] [Related]

  • 4. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.
    Br J Pharmacol; 2009 Nov 01; 158(6):1536-47. PubMed ID: 19845677
    [Abstract] [Full Text] [Related]

  • 5. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
    Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM.
    J Clin Pharmacol; 2011 Apr 01; 51(4):561-74. PubMed ID: 20622200
    [Abstract] [Full Text] [Related]

  • 6. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR, Rettie AE, Brundage RC, Tracy TS.
    J Clin Pharmacol; 2017 Mar 01; 57(3):382-393. PubMed ID: 27539372
    [Abstract] [Full Text] [Related]

  • 7. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
    Circulation; 2009 Sep 22; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
    Wang F, Guo J, Zhang A.
    J Cardiovasc Pharmacol; 2019 Mar 22; 73(3):127-135. PubMed ID: 30688796
    [Abstract] [Full Text] [Related]

  • 9. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.
    Zhou Q, Wang Z, Wang H, Chen Z, Li X, Dai X, Zhang Y, Yu X, Zhou R, Hu W.
    Am J Cardiovasc Drugs; 2023 Jan 22; 23(1):101-112. PubMed ID: 36622539
    [Abstract] [Full Text] [Related]

  • 10. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.
    Can J Cardiol; 2013 Jul 22; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [Abstract] [Full Text] [Related]

  • 11. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
    Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H.
    Clin Drug Investig; 2011 Jul 22; 31(3):169-79. PubMed ID: 21184622
    [Abstract] [Full Text] [Related]

  • 12. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS.
    J Clin Pharmacol; 2001 Jul 22; 41(7):715-22. PubMed ID: 11452703
    [Abstract] [Full Text] [Related]

  • 13. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
    Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H.
    Pharmacogenomics; 2015 Jul 22; 16(3):217-25. PubMed ID: 25712185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of cucurbitacin e, a tetracyclic triterpene compound from Cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats.
    Ding T, Zhang Y, Chen A, Tang Y, Liu M, Wang X.
    Basic Clin Pharmacol Toxicol; 2015 May 22; 116(5):385-9. PubMed ID: 25250504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.
    Pediatr Blood Cancer; 2014 Jun 22; 61(6):1055-62. PubMed ID: 24474498
    [Abstract] [Full Text] [Related]

  • 18. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D.
    Clin Pharmacol Ther; 2001 Aug 22; 70(2):159-64. PubMed ID: 11503010
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.